<DOC>
	<DOCNO>NCT02914223</DOCNO>
	<brief_summary>The main objective study investigate rate route elimination cenerimod mass balance urine , feces , expire air</brief_summary>
	<brief_title>A Study Evaluate Cenerimod Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent language understandable subject prior studymandated procedure Healthy male subject age 45 65 year ( inclusive ) screen No clinically significant finding physical examination screen Body mass index ( BMI ) 18.0 30.0 kg/m2 ( inclusive ) screen Systolic blood pressure ( SBP ) 100145 mmHg diastolic blood pressure ( DBP ) 5090 mmHg , measure either arm , 5 min supine position screen Day 1 predose Heart rate ( HR ) 5590 bpm ( inclusive ) measure 12lead ECG 5 min supine position screen Day 1 predose Known hypersensitivity cenerimod S1P receptor modulators , excipients cenerimod drug formulation History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism , excretion study treatment ( appendectomy herniotomy allow , cholecystectomy allow ) History clinical evidence suggestive active latent tuberculosis include positive QuantiFERON®TB test screen Any cardiac condition illness ( include 12lead ECG abnormality ) potential increase cardiac risk subject base standard 12lead ECG screen Day 1 predose Participation another study radiation burden &gt; 0.1 mSv ≤ 1 mSv period 1 year prior screening ; radiation burden ≥ 1.1 mSv ≤ 2 mSv period 2 year prior screen , etc . ( add 1 year per 1 mSv ) Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol Any immunosuppressive treatment within 6 week within 5 elimination halflives immunosuppressive treatment , whichever longer , study treatment administration</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>